{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:52:56Z","timestamp":1788839576914,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Cheery Pharma Co. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10637-020-01057-3","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T12:39:07Z","timestamp":1610368747000},"page":"747-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A rat toxicological study of intra-arterial injection of Tirapazamine, a hypoxia-activating Cancer therapeutic agent, followed by hepatic artery ligation"],"prefix":"10.1007","volume":"39","author":[{"given":"Chang-Hsien","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Juei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"6","key":"1057_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bjc.1993.220","volume":"67","author":"JM Brown","year":"1993","unstructured":"Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67(6):1163\u20131170","journal-title":"Br J Cancer"},{"issue":"1 Suppl 4","key":"1057_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/sonc.2002.31531","volume":"29","author":"DR Gandara","year":"2002","unstructured":"Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH (2002) Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29(1 Suppl 4):102\u2013109. https:\/\/doi.org\/10.1053\/sonc.2002.31531","journal-title":"Semin Oncol"},{"issue":"1","key":"1057_CR3","first-page":"31","volume":"3","author":"S Senan","year":"1997","unstructured":"Senan S, Rampling R, Graham MA, Wilson PJ, Robin H, Eckardt NA, Lawson N, McDonald AD, Roemeling RV, Workman P, Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3(1):31\u201338","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ygyno.2005.09.032","volume":"100","author":"A Covans","year":"2006","unstructured":"Covans A, Blessing J, Bender D, Mannel R, Morgan M (2006) A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 100(3):586\u2013590. https:\/\/doi.org\/10.1016\/j.ygyno.2005.09.032","journal-title":"Gynecol Oncol."},{"issue":"3","key":"1057_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1525-1438.2006.00454.x","volume":"16","author":"FC Maluf","year":"2006","unstructured":"Maluf FC, Leiser AL, Aghajanian C, Sabbatini P, Pezzulli S, Chi DS, Wolf JK, Levenback C, Loh E, Spriggs DR (2006) Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16(3):1165\u20131171. https:\/\/doi.org\/10.1111\/j.1525-1438.2006.00454.x","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"1057_CR6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/cncr.21785","volume":"106","author":"QT Le","year":"2006","unstructured":"Le QT, Taira AL, Budenz S, Jo Dorie M, Goffinet DR, Fee WE, Goode R, Bloch D, Koong A, Martin Brown J, Pinto HA (2006) Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer. 106(9):1940\u20131949. https:\/\/doi.org\/10.1002\/cncr.21785","journal-title":"Cancer."},{"issue":"36","key":"1057_CR7","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1200\/JCO.2005.01.3771","volume":"23","author":"SK Williamson","year":"2005","unstructured":"Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR (2005) Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: southwest oncology group trial S0003. J Clin Oncol 23(36):9097\u20139104. https:\/\/doi.org\/10.1200\/JCO.2005.01.3771","journal-title":"J Clin Oncol"},{"issue":"18","key":"1057_CR8","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","volume":"28","author":"D Rischin","year":"2010","unstructured":"Rischin D, Peters LJ, O\u2019Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the trans-Tasman radiation oncology group. J Clin Oncol 28(18):2989\u20132995. https:\/\/doi.org\/10.1200\/JCO.2009.27.4449","journal-title":"J Clin Oncol"},{"issue":"5","key":"1057_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","volume":"32","author":"PA DiSilvestro","year":"2014","unstructured":"DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM (2014) Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a gynecologic oncology group study. J Clin Oncol 32(5):458\u2013464. https:\/\/doi.org\/10.1200\/JCO.2013.51.4265","journal-title":"J Clin Oncol"},{"issue":"6","key":"1057_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00270-011-0156-4","volume":"34","author":"A Sonada","year":"2011","unstructured":"Sonada A, Nitta N, Ohta S, Nagatani Y, Takahashi M, Marata K (2011) Enhanced antitumor effect of tirapazamine delivered intraperitoneally to VX2 liver tumor-bearing rabbits subjected to transarterial hepatic embolization. Cardiovasc Intervent Radiol 34(6):1272\u20131277. https:\/\/doi.org\/10.1007\/s00270-011-0156-4","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"42","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"11937","DOI":"10.1073\/pnas.1613466113","volume":"113","author":"WH Lin","year":"2016","unstructured":"Lin WH, Yeh SH, Yeh KH, Chen KW, Cheng YW, Su TH, Jao P, Ni LC, Chen PJ, Chen DS (2016) Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. Proc Natl Acad Sci U S A 113(42):11937\u201311942. https:\/\/doi.org\/10.1073\/pnas.1613466113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1057_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/SLA.0b013e318295c160","volume":"259","author":"KM Govaert","year":"2014","unstructured":"Govaert KM, Emmink BL, Nijkamp MW, Cheung ZJ, Steller EJA, Fatrai S, de Bruijn MT, Kranenburg O, Rinkes IHMB (2014) Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg 259(4):750\u2013759","journal-title":"Ann Surg"},{"issue":"1","key":"1057_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002800050617","volume":"40","author":"MA Graham","year":"1997","unstructured":"Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, Von Roemeling R, Workman P (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40(1):1\u201310","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01057-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:04:05Z","timestamp":1678511045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01057-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}